deaths (OS)

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)

versus Standard of Care (SoC)
capivasertib plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-58%

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus Standard of Care (SoC)
capivasertib plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-36%
ipatasertib plus paclitaxel vs. Standard of Care (SoC) 1 certainty unassessable-18%

mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive